[ad_1]
DUBLIN, September 18, 2018 / PRNewswire / –
The report "The Market for Non-opioid Drugs for Pain Management and Chronic Pain, 2018-2025" was added to ResearchAndMarkets.com & # 39; s offer.
The report "Non-opioid Medications for Chronic Pain and Pain Management Devices, 2018-2025" provides a comprehensive review of marketed, clinical and preclinical product / product candidates for the management of chronic pain . The report also provides a detailed overview of devices used for the treatment / management of pain associated with chronic clinical conditions.
Due to the rapid onset of their medicinal effect, which provides immediate relief and high efficacy, opioids are still considered one of the most widely used pharmacological interventions for the management of moderate to severe forms of pain. However, these drugs are known to induce a euphoric state when taking, often causing abuse in patients; Increased use of opioids for recreational purposes has also proven to lead to addiction.
The excessive prescription of these drugs, which promotes their misuse, is considered one of the root causes of the opioid crisis. In a recent article published in 2017, 11.5 million individuals would have been caught using prescription opioids, while more than 42,000 would have died from an overdose of Opioids, nothing that in the United States. In addition, opioid abuse has been responsible for more than 500 billion USD Value of the economic deficit (in the United States) due to lost productivity and health costs.
The opioid crisis has prompted drug manufacturers to develop non-addictive therapies / analgesics for pain management. Unlike opioids, non-opioid drugs do not affect receptors in the brain and therefore do not create dependence. These drugs act directly on the injured / diseased body tissues and generally block the production of prostaglandins by inhibiting the enzyme cyclooxygenase (COX) at the site of the lesion / infection, thereby decreasing the production of pain mediators in the peripheral nervous system.
In addition, it has been reported that various pain management devices significantly reduce or eliminate the need for pharmacological interventions. Such devices are increasingly used to treat various clinical conditions characterized by chronic pain and which can also be used in home care. However, it is imperative for patients to consult with qualified health professionals, who have the required understanding of these therapeutic options, before using such devices.
One of the main objectives of the report was to understand the main factors of growth and to estimate the future size of the market. Based on metrics such as target consumer segments, likely adoption rates, and forecast prices, we provided an informed estimate of the likely short- and medium-term market developments for 2018-2025. The report includes a detailed segmentation of the market based on indications (chronic back pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), type of molecule (small molecule and biological product), mechanism of action (inhibitors of CGRP, COX / NGF inhibitors, TRPV1). receptor antagonists, channel blockers and others) and geography (North America, Europe , Asia Pacific and rest of the world). In addition, the report presents an analysis of opportunities for the market for chronic pain management devices.
The opinions and points of view presented in this study were influenced by the contributions solicited through a comprehensive survey and discussions with several key players in this area. The report presents detailed transcripts of interviews with Ryan Jeffcoat (Director of Clinical Affairs and New Markets, AVACEN Medical), Lisa Robin (Advocacy Officer, Federation of State Medical Commissions), Nelson Hendler (General Manager, Mensana Clinic Diagnostics) and Mark Wiederhold (General Manager, Virtual Reality Medical Center). All actual figures were obtained and analyzed from publicly available information forums and information from primary research. The financial figures mentioned in this report are in USD unless otherwise indicated.
Key topics covered:
1. PREFACE
1.1. Scope of the report
1.2. Research Methodology
1.3. Chapter Outlines
2. SUMMARY
3. INTRODUCTION
3.1. Definition of pain
3.2. Classification of pain
3.2.1. Acute pain
3.2.2. Chronic pain
3.2.2.1. Classification of chronic pain
3.2.2.2. Chronic pain and mental health
3.3. Pain management
3.3.1. Therapeutics for pain management
3.3.2. Devices for pain management
3.3.3. Other therapeutic modalities and interventions for pain management
3.4. Outlook for the future
4. CHRONIC MANAGEMENT OF PAIN: ANALYSIS OF UNMET NEEDS
4.1. Chapter overview
4.2. Needs analysis not satisfied
4.2.1. introduction
4.2.2. Patient Blogs
4.2.3. Published literature
4.2.4. Social media platforms
4.2.5. Expert Reviews
4.2.5.1. Jeffrey Curtis, MD, University of Alabama
4.2.5.2. Stephan Silberstein, MD, Jefferson University Hospital
4.2.5.3. Jeffrey Gudin, MD, Englewood Hospital and Medical Center
4.2.5.4. Kevin Zacharoff, MD, SUNY Stonybrook School of Medicine
4.2.5.5. Philip J Mease, MD, University of Washington Medicine School
4.2.5.6. John D Reveille, MD, McGovern School of Medicine
4.2.5.7. Christopher R McCurdy, PhD, University of Florida
4.2.6. Concluding remarks: Main unmet needs in chronic pain management
5. PIPELINE REVIEW: MARKETED MEDICINES AND DEVELOPMENT
5.1. Chapter overview
5.2. Non-opioid Drugs for Chronic Pain Management: Marketed Pipeline and Development
5.3. Non-opioid Drugs for Chronic Pain Management: Pipeline Analysis
5.3.1. Analysis by development phase
5.3.2. Analysis by molecule type
5.3.3. Analysis by mechanism of action
5.3.4. Analysis by way of administration
5.3.5. Analysis by therapeutic target Indication (s)
5.3.6. Analysis by size of basic developer employee
5.3.7. Pipeline Analysis: Key Actors
5.3.8. Landscape Developer Logo: Distribution by Size and Location
5.3.9. Mirroring: distribution by type of indication, number of molecules and manufacturer
5.3.10. Representation of Heptagon: Distribution by Target Disease Indication and Development Phase
5.3.11. Funnel analysis: distribution by indication of target diseases, route of administration and development phase
6. LIFE CYCLE MANAGEMENT STRATEGIES FOR COMMERCIALIZED PRODUCTS
6.1. introduction
6.2. Product Profile: Duexis (Horizon Pharma)
6.2.1. Overview
6.2.2. Mechanism of Action
6.2.3. Life Cycle Management Strategies
6.2.4. Partnerships and collaborations
6.3. Product Profile: Grid (Depomed)
6.3.1. Overview
6.3.2. Mechanism of Action
6.3.3. Life Cycle Management Strategies
6.3.4 Legal Defense
6.3.5. Partnerships and collaborations
6.3.5.1. Actavis
6.3.5.2. Abbott
6.4. Product Profile: Horizant (Arbor Pharmaceuticals)
6.4.1. Overview
6.4.2. Mechanism of Action
6.4.3. Life Cycle Management Strategies
6.4.3.1. Extension of patent exclusivity
6.4.3.2. Extension of the indication
6.4.4. New dose strength
6.4.5. Partnerships and collaborations
6.4.5.1. GlaxoSmithKline
6.4.5.2. Arbor Pharmaceutical
6.5. Product Profile: Vimovo (AstraZeneca and Pozen)
6.5.1. Overview
6.5.2. Mechanism of Action
6.5.3. Life Cycle Management Strategies
6.5.3.1. Price
6.5.3.2. Geographic expansion
6.5.4. Legal Defense
6.5.5. Partnerships and collaborations
6.5.5.1. AstraZeneca
6.5.5.2. Horizon Pharma
7. DRUG PROFILES: STAGE MOLECULES
7.1. Chapter overview
7.2. Drug Profile: Aimovig / Erenumab
7.3. Drug profile: Analgecine
7.4. Drug profile: Atogepant / AGN 241689 / MK 8031
7.5. Drug profile: Civamide / Civanex / Zucapsaicin
7.6. Drug profile: CNTX-4975
7.7. Drug profile: Eptinezumab / ALD403
7.8. Drug profile: Fasinumab
7.9. Drug Profile: Fremanezumab
7.10. Drug profile: Galcanezumab / LY2951742
7.11. Drug Profile: Lasmiditan / COL-144
7.12. Drug profile: Mirogabalin / DS-5565
7.13. Drug profile: MPC-06-ID
7.14. Drug profile: Neridronate
7.15. Drug profile: NTM-001
7.16. Drug profile: NTM-002
7.17. Drug Profile: Perampanel (E2007)
7.18. Drug profile: POSIMIR (SABER-Bupivacaine)
7.19. Drug profile: Ralfinamide
7.20. Drug profile: SP-102
7.21. Drug profile: T-121
7.22. Drug Profile: Tanezumab
7.23. Drug profile: Tetrodotoxin / TTX
7.24. Drug Profile: Ubrogepant / MK-1602
7.25. Drug profile: YHD1119 / PREGABALIN
8. CHRONIC PAIN MANAGEMENT DEVICES: MARKET LANDSCAPE
8.1. Chapter overview
8.2. Pain management devices: database
8.3. Pain Management Devices: Database Analysis
8.3.1. Analysis by type of device
8.3.2. Analysis by mechanism of action
8.3.3. Per device modality analysis
8.3.4. Analysis by site of application on the body
8.3.5. Analysis for convenience of use
8.3.6. Location Analysis of Developers
8.3.7. Analysis by size of company
9. ANALYSIS OF THE COMPETITIVENESS OF DEVICES AND PROFILES
9.1. Chapter overview
9.2. Methodology
9.3. Implants
9.3.1. Assumptions, limits and main evaluable parameters
9.3.2 Competitive analysis of the device for implants: results
9.3.3. Device Profiles
9.3.3.1. Freedom SCS System (Stimwave)
9.3.3.2. VIVENDI (BlueWind Medical)
9.4. wearables
9.4.1. Assumptions, limits and parameters evaluated
9.4.2. Competitive Device Analysis for Wearables: Results
9.4.3. Device Profiles
9.4.3.1. Avail Wireless (Omron Healthcare)
9.4.3.2. Cefaly (Cefaly Technologies)
9.4.3.3. Electro-Mesh Garments (Prizm Medical)
9.4.3.4. Micro-Z (Prizm Medical)
9.4.3.5. PainPod MI (PainPod)
9.4.3.6. PainPod XPV (PainPod)
9.4.3.7. Quell Relief (Neurometrix)
9.4.3.8. SENSUS Pain Management System (Neurometrix)
9.4.3.9. Smart Relief Back (Chattem)
9.5. Other devices
9.5.1. Assumptions, limits and parameters evaluated
9.5.2. Competitive Analysis of Peripherals for Other Devices: Results
9.5.3. Device Profiles
9.5.3.1. Silk's N Relief (Silk's Therapy)
9.5.3.2. The Wellness Pro Plus (ElectroMedical Technologies)
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter overview
10.2. Partnership models
10.3. Non-opioid Drugs and Devices for Chronic Pain Management: Recent Partnerships and Collaborations
10.3.1. Analysis by year of agreement
10.3.2. Quarterly trend analysis
10.3.3. Analysis by type of partnership
10.3.4. Analysis by the most active players
10.3.5. Analysis by geographical activity
11. ANALYSIS OF FINANCING AND INVESTMENT
11.1. Chapter overview
11.2. Types of financing
11.3. Non-opioid Drugs for Chronic Pain Management: Analysis of Funding and Investment
11.3.1. Cumulative Number Analysis of Funding Instances
11.3.2. Analysis by cumulative amount invested
11.3.3. Analysis by type of financing
11.3.4. Analysis by the most active players
11.3.5. Analysis by the most active investors
11.4. Final remarks
12. MARKET FORECASTS AND ANALYSIS OF OPPORTUNITIES
12.1. Chapter overview
12.2. Key assumptions
12.3. Forecast methodology
12.4. Global non-opioid drug market for chronic pain management, 2018-2025
12.4.1. Non-opioid drug market: breakdown by therapeutic area
12.4.2. Non-opioid drug market: distribution by molecule type
12.4.3. Non-opioid drug market: breakdown by mechanism of action
12.4.4. Non-opioid drug market: geographical distribution
12.5. Non-opioid Drug Market: Product Sales Forecasts
12.5.1. Qutenza (Accorda Therapeutics)
12.5.2. Vimovo (Horizon Pharma)
12.5.3. Duexis (Horizon Pharma)
12.5.4. Grid (Depomed)
12.5.5. Horizant (Arbor Pharmaceuticals)
12.5.6. Zilretta (Flexion Therapeutics)
12.5.7. Ztlido (Sorrento Therapeutics)
12.5.8. Aimovig (Amgen)
12.5.9. Fremanezumab (Teva Pharmaceuticals)
12.5.10. Galcanezumab (Eli Lilly)
12.5.11. Mirogabaline (DS-5565) (Daiichi Sankyo)
12,5.12. YHD1119 (Yuhan company)
12.5.13. GLA5PR (GL PharmTech)
12.5.14. Eptinezumab (Alder Biopharmaceuticals)
12.5.15. ALLOD-2 (allodynic therapy)
05/12/16. PainBrake (GT Biopharma)
05/12/17. Neridronate (Grunenthal)
05/12/18. Fasinumab (Regeneron Pharmaceuticals)
05/12/19. SP-102 (Semnur Pharmaceuticals)
05/12/20. CNTX-4975 (Centrexion Therapeutics)
05/12/21. MPC-06-ID (Mesoblast)
12.5.22. tanezumab
12.6. Global Market for Pain Management Devices, 2018-2025
12.6.1. Market for Pain Management Devices: Geographic Distribution
12.6.2. Market of pain management devices: breakdown by type of device
12.6.3. Market of pain management devices: breakdown by mechanism of action
13. CONCLUSION
13.1. The opioid crisis is responsible for a number of deaths due to the abuse of controlled substances; Drug developers are actively trying to develop alternative pain management solutions
13.2. The non-opioid drug market is characterized by a strong pipeline of drug candidates under development in a variety of chronic clinical conditions
13.3. A variety of innovative devices are also available for the management of various clinical conditions characterized by chronic pain
13.4. The increase in partnership activity and the financial support of various investors indicate a future lucrative potential
13.5. Given existing unmet needs, the market is expected to grow steadily in the foreseeable future
14. EXECUTIVE SUMMARY
14.1. Chapter overview
14.2. Mark WiederholdChief Executive Officer, Virtual Reality Medical Center (Q2 2018)
14.3. Lisa Robin, Advocacy Officer, Federation of Medical Boards of the State (Q2 2018)
14.4. Nelson HendlerGeneral Manager of Mensana Clinic Diagnostics (Q2 2018)
14.5. Ryan Jeffcoat, Director of Clinical Affairs and New Markets, AVACEN Medical (Q1 2018)
For more information on this report, visit https://www.researchandmarkets.com/research/lctv29/global_nonopioid?w=5.
Did you know that we also offer a personalized search? Visit our Custom Search page to learn more and schedule a meeting with our Custom Search Manager.
Media contact:
Laura WoodSenior Director
[email protected]
For E.S.T office hours, call + 1-917-300-0470
To call toll free in the United States and Canada + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
American fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
Source link
